Increased Dietary Leucine Reduces Doxorubicin-Associated Cardiac Dysfunction in Rats
Autor: | Luciano Alex dos Santos, Hanna Karen Moreira Antunes, Thiago Montes Fidale, Matheus M. Mantovani, Simone Ramos Deconte, Francyelle Borges Rosa de Moura, Elmiro Santos Resende, Fernanda Rodrigues de Souza, Poliana Rodrigues Alves Duarte, Leonardo Roever |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Physiology Cardiomyopathy cardiotoxicity heart failure 030204 cardiovascular system & hematology doxorubicin lcsh:Physiology 03 medical and health sciences 0302 clinical medicine Physiology (medical) Internal medicine Medicine Doxorubicin BCAA Original Research Cardiotoxicity Ejection fraction lcsh:QP1-981 Cumulative dose business.industry medicine.disease 030104 developmental biology medicine.anatomical_structure Endocrinology Ventricle Heart failure Leucine leucine business medicine.drug |
Zdroj: | Frontiers in Physiology, Vol 8 (2018) Frontiers in Physiology |
Popis: | Cardiotoxicity is one of the most significant adverse effects of the oncologic treatment with doxorubicin, which is responsible for a substantial morbid and mortality. The occurrence of heart failure with ventricular dysfunction may lead to severe cardiomyopathy and ultimately to death. Studies have focused on the effects of leucine supplementation as a strategy to minimize or revert the clinical condition of induced proteolysis by several clinical onsets. However, the impact of leucine supplementation in heart failure induced by doxorubicin is unknown. Therefore, the objective of this work is to evaluate the effects of leucine supplementation on the cardiotoxicity in the heart of rats treated with doxorubicin. Rats treated with a 7.5 mg/kg cumulative dose of doxorubicin for 14 days presented a dilatation of the left ventricle (LV), and a reduction of the ejection fraction (FE). The 5% supplementation of leucine in the rats' food prevented the malfunctioning of the LV when administered with doxorubicin. Some alterations in the extracellular matrix remodeling were confirmed by the increase of collagen fibers in the doxorubicin group, which did not increase when the treatment was associated with leucine supplementation. Leucine attenuates heart failure in this experimental model with doxorubicin. Such protection is followed by the maintenance of interstitial collagen fibers. |
Databáze: | OpenAIRE |
Externí odkaz: |